Business Context and Reporting Period
This Form 8-K, dated April 14, 2023, reports the consummation of a merger by SS Innovations International, Inc. (formerly Avra Medical Robotics, Inc.) with CardioVentures, Inc. The transaction resulted in a change of control, with the company renaming itself to SS Innovations International, Inc. and shifting its primary business focus to the development and commercialization of the "SSI Mantra" surgical robotic system through its Indian subsidiary, SSI-India. All share data reflects a one-for-ten reverse stock split effective April 17, 2023.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Financial statements for the acquired business and pro forma information are scheduled to be filed within 75 days. Key capital structure changes include:
- Equity Issuance: CardioVentures shareholders received 135,808,884 shares of common stock (approx. 95% post-merger ownership).
- Existing Shareholders: Retained approximately 6,544,344 shares (approx. 5% post-merger ownership).
- Preferred Stock: Issued Series A Non-Convertible Preferred Stock to CardioVentures holders, granting 51.0% of total voting power.
- Interim Financing: Issued 3,818,028 shares to Dr. Frederic Moll in exchange for $3,000,000 in interim financing.
- Authorized Stock: Increased authorized common stock to 250,000,000 shares.
Material Changes Versus Prior Period
The company underwent a fundamental transformation:
- Change in Control: Dr. Sudhir Srivastava became the principal and controlling shareholder.
- Management Overhaul: Former CEO Barry F. Cohen, COO Dr. Ray Powers, and CMO Dr. Farhan Taghizadeh resigned. Dr. Sudhir Srivastava assumed the roles of Chairman and CEO; Dr. Vishwajyoti P. Srivastava became President and COO-South Asia; Anup Sethi became CFO.
- Corporate Name: Changed from Avra Medical Robotics, Inc. to SS Innovations International, Inc.
- Intellectual Property: Dr. Srivastava assigned patents and trademarks to a subsidiary in exchange for a 3% quarterly royalty on net revenues.
Outlook, Risks, and Unusual Items
Outlook: The company intends to globally expand its surgical robotic solutions, focusing on affordability and accessibility. The SSI Mantra system was commercially introduced in August 2022.
Compensation Obligations: New executive employment agreements were executed with annual base salaries totaling $975,000 ($600,000 for CEO, $200,000 for President/COO, $175,000 for CFO).
Risks and Contingencies:
- Voting Control: Series A Preferred Shareholders hold 51% of voting power, though these shares are non-convertible and have nominal liquidation preference.
- Financial Reporting: Historical financial data for the acquired entity is not yet available in this filing.
- Reverse Stock Split: A 1-for-10 split was effected to adjust share count.
Investor Verification Checklist
- Verify the upcoming filing of CardioVentures' financial statements and pro forma information (due within 75 days).
- Confirm the terms and redemption triggers for the Series A Non-Convertible Preferred Stock.
- Review the 3% royalty agreement on net revenues paid to Dr. Srivastava's holding company.
- Assess the impact of the new executive compensation structure on future operating expenses.
- Monitor the commercial adoption rates of the SSI Mantra surgical robotic system.